Two-year probability of losing the CCyR and imatinib failure (EFS) according to the adherence rate and to the combination of adherence and the prior achievement of MMR. The 18 patients with an adherence rate ≤85% had higher 2-year probability of both losing their CCyR (A; 36.3% vs 1.4%, P < .0001) and of failing imatinib therapy (C; 54.4% vs 91.4%, P = .0002) than the 69 patients with an adherence rate >85%. The 53 patients who had achieved MMR at the moment of enrollment had a similar 2-year probability of losing their CCyR during follow-up (B) and a 2-year EFS (D) to that of the 23 patients who were not in MMR at enrollment but had an adherence rate >85% (0% vs 4.3%, P = .31; and 94.4% vs 86.1%, P = .14). However, the 11 patients who were not in MMR at the moment of enrollment and had an adherence rate ≤85% had a significantly higher probability of losing their CCyR (54.5%) and lower EFS (28.3%) (B,D).